Doximity (DOCS), a digital health platform serving healthcare professionals, has experienced a significant 66% decline over the past year as software equities faced broader market pressures amid artificial intelligence-related concerns. Despite the stock decline, the company's operational metrics remain robust, with gross margins at 89.75% and EBIT margins of 38.5%, positioning it among the more profitable software-as-a-service operators.
The platform maintains a commanding market presence, reaching approximately 85% of U.S. physicians through its social network and software tools. The company's valuation has compressed to a P/E multiple of 21x, a significant discount from historical levels for high-margin software businesses. Doximity continues to expand its product ecosystem, including recent launches in generative AI-powered tools designed to streamline clinical workflows.
Analysts point to the disconnect between the company's market valuation and its underlying business strength as investors reassess technology sector risks. The platform's entrenched position in healthcare and strong unit economics suggest the business fundamentals remain independent of recent market volatility affecting growth-stage software companies.